- Home
- TBHC vs MRSN Comparison
TBHC vs MRSN Comparison
Compare TBHC & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBHC
- MRSN
- Stock Information
- Founded
- TBHC 1966
- MRSN 2001
- Country
- TBHC United States
- MRSN United States
- Employees
- TBHC N/A
- MRSN N/A
- Industry
- TBHC Other Specialty Stores
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- TBHC Consumer Discretionary
- MRSN Health Care
- Exchange
- TBHC Nasdaq
- MRSN Nasdaq
- Market Cap
- TBHC 32.3M
- MRSN 37.0M
- IPO Year
- TBHC N/A
- MRSN 2017
- Fundamental
- Price
- TBHC $1.50
- MRSN $7.32
- Analyst Decision
- TBHC
- MRSN Strong Buy
- Analyst Count
- TBHC 0
- MRSN 4
- Target Price
- TBHC N/A
- MRSN $63.67
- AVG Volume (30 Days)
- TBHC 160.6K
- MRSN 97.8K
- Earning Date
- TBHC 09-16-2025
- MRSN 08-13-2025
- Dividend Yield
- TBHC N/A
- MRSN N/A
- EPS Growth
- TBHC N/A
- MRSN N/A
- EPS
- TBHC N/A
- MRSN N/A
- Revenue
- TBHC $431,111,000.00
- MRSN $34,769,000.00
- Revenue This Year
- TBHC N/A
- MRSN N/A
- Revenue Next Year
- TBHC N/A
- MRSN N/A
- P/E Ratio
- TBHC N/A
- MRSN N/A
- Revenue Growth
- TBHC N/A
- MRSN 16.14
- 52 Week Low
- TBHC $1.20
- MRSN $5.21
- 52 Week High
- TBHC $1.73
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- TBHC N/A
- MRSN 48.13
- Support Level
- TBHC N/A
- MRSN $7.41
- Resistance Level
- TBHC N/A
- MRSN $8.05
- Average True Range (ATR)
- TBHC 0.00
- MRSN 0.60
- MACD
- TBHC 0.00
- MRSN 0.10
- Stochastic Oscillator
- TBHC 0.00
- MRSN 70.73
About TBHC The Brand House Collective Inc. Common Stock
The Brand House Collective Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.